ABBV vs MELI: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-16.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,828.94
+25.8% upside to fair value
Med Conviction
Grade B+
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+25.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MELI |
| Current Price |
$261.70 |
$1,828.94 |
| Fair Value Estimate |
$259.04 |
$2,300.00 |
| Upside to Fair Value |
-1.0%
|
+25.8%
|
| Market Cap |
$462.4B |
$92.7B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
33.0x
|
| Price / Sales |
7.2x
|
2.6x
|
| Price / FCF |
23.6x
|
7.4x
|
| Revenue Growth YoY |
+10.2%
|
+49.8%
|
| Gross Margin |
71.5%
|
42.7%
|
| Operating Margin |
29.3%
|
8.3%
|
| Return on Equity |
-136.5%
|
26.5%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
13.44%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
MercadoLibre operates Latin America's leading ecommerce marketplace alongside Mercado Pago payments, credit, logistics, advertising and loyalty products, creating a broad ecosystem with meaningful network effects and cross-sell. Business momentum remains strong: revenue and financial income grew 49.8% year over year in the most recent quarter to $10.169 billion, GMV increased 44%, TPV rose 56%, a…
Accumulation Zones
| Metric |
ABBV |
MELI |
| Zone Low |
$194.28 |
$1,725.00 |
| Zone High |
$220.18 |
$1,955.00 |
| In Buy Zone? |
No
|
Yes
|